New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:00 EDTBSXBoston Scientific upgraded at Oppenheimer
As previously reported, Oppenheimer upgraded Boston Scientific to Overweight from Equal Weight. The firm upgraded shares to reflect pipeline acceleration and margin improvement in cardiology. Price target is $15.
News For BSX From The Last 14 Days
Check below for free stories on BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
15:39 EDTBSXBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
April 15, 2014
16:47 EDTBSXBoston Scientific announces FDA approval for defibrillators
Subscribe for More Information
11:53 EDTBSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Subscribe for More Information
09:23 EDTBSXBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2014
10:02 EDTBSXOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
06:44 EDTBSXBoston Scientific upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
06:18 EDTBSXBoston Scientific upgraded to Buy from Neutral at BofA/Merrill
Price target is $16.
April 10, 2014
18:34 EDTBSXBoston Scientific enrolls first patient in registry for evaluating Vercise DBS
Subscribe for More Information
April 7, 2014
18:01 EDTBSXBoston Scientific gets FDA, CE Mark clearance for Expect Slimline Needle
Boston Scientific announced it has received clearance from the U.S. FDA and CE Mark approval in Europe for the Expect Slimline Needle, which is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration procedures. The Expect Slimline Needle is on contract with four leading group purchasing organizations.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use